Recall of Omega-3-Acid Ethyl Esters Capsules
The Harvard Drug Group LLC is voluntarily recalling 2,238 cartons of Omega-3-Acid Ethyl Esters Capsules due to failed capsule specifications from routine stability testing.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on May 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — FDA Recalls — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA recall is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, cpsc, Drugs) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What Happened
The recall was initiated because of failed capsule specifications, specifically out of specification results for Loss on Drying of Capsule Shells during routine stability testing.
Which Products Are Affected
The affected product is Omega-3-Acid Ethyl Esters Capsules, USP, 1 gram, 50 capsules (5 x 10 unit dose blister cards) per carton, distributed by Major Pharmaceuticals, Indianapolis, IN 46288, with NDC 0904-7495-06. A total of 2,238 cartons are involved, affecting Lot N02406 (expiration 10/31/2026) and Lot N02845 (expiration 12/31/2026). The product was distributed nationwide in the USA.
What You Should Do
Consumers should contact the recalling firm, The Harvard Drug Group LLC, for instructions, as the initial notification was made via letter. Stop using the affected lots and follow the firm's guidance for returns or refunds.
Why This Matters
This recall involves a prescription drug with potential quality issues that could affect its efficacy, highlighting the importance of proper manufacturing standards in pharmaceuticals to ensure patient safety.
Source
FDA Recall Number D-0493-2026
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.